Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
An event-related potential study using a cued task-switching paradigm reveals neural correlates of cognitive flexibility impairments in schizophrenia. [PDF]
Mei Q +7 more
europepmc +1 more source
Event-related potentials recorded during the discrimination of improbable stimuli
Peter L. Fitzgerald, Terence W. Picton
openalex +1 more source
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Coupling of Event-Related Potential and Pupil Dilation as a Compensatory Marker of Executive Attention in Traumatic Brain Injury. [PDF]
Scanavini G +11 more
europepmc +1 more source
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Effect of resistance exercise on attentional bias toward food in overweight female college students: An event-related potential study. [PDF]
Wang J, Ding F, Lian S, Yu L.
europepmc +1 more source
Event-related potential studies of prefrontal cortex contributions to episodic retrieval [PDF]
Damian Cruse
openalex
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source

